COMMUNIQUÉS West-GlobeNewswire

AsymBio Completes its Dual-Site, One-Center Network with Fengxian Commercial Manufacturing Site Operational, Enhancing End-to-End Biologics CDMO Capabilities
09/03/2026
SHANGHAI, March 09, 2026 (GLOBE NEWSWIRE) -- AsymBio, a subsidiary of Asymchem Group (stock code: 002821.SZ / 6821.HK ), recently announced that its Fengxian commercial manufacturing site in Shanghai has officially [...]
LB Pharmaceuticals Appoints R&D Biotech Executive Robert Lenz, M.D., Ph.D. to Board of Directors
09/03/2026
Dr. Robert Lenz brings over 20 years of experience in neuroscience drug development NEW YORK, March 09, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late- [...]
SS Innovations Announces Completion of an $18.6 Million Private Placement to Support Growth Initiatives
09/03/2026
Financing led by Certain of the Company’s Directors and Executive Officers FORT LAUDERDALE, Fla., March 09, 2026 (GLOBE NEWSWIRE) -- SS Innovations International, Inc. (the “Company” or “SS Innovations”) (Nasdaq: SSII [...]
Poster Presentation Demonstrating Combination Benefit of Narmafotinib in Preclinical Kras-Mutated Cancer Models
09/03/2026
HIGHLIGHTS Amplia’s lead drug narmafotinib enhances the activity of kRAS inhibitors in multiple preclinical cancer models presented at US conference Data showing narmafotinib activity in preclinical models of pancreatic [...]
Cloudcure Launches Companion App to Close Clinical Adherence Gap in Metabolic Health
09/03/2026
Toronto, ON, March 09, 2026 (GLOBE NEWSWIRE) -- Cloudcure, a specialized health platform dedicated to improving metabolic health through evidence-based, personalized medicine, has announced the launch of its new weight [...]
Keros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific Conference
09/03/2026
LEXINGTON, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel [...]
Cue Biopharma to Present New In vitro Data for CUE-401 at the 20th World Immune Regulation Meeting (WIRM) 2026
09/03/2026
BOSTON, March 09, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease- [...]
SpyGlass Pharma Announces Positive Topline 12-Month Phase 1/2 Trial Results for Its Innovative BIM-IOL System
09/03/2026
97% of patients who received the BIM-IOL System off all topical IOP-lowering therapy at 12-months 100% of BIM-IOL System patients achieved 20/32 or better BCDVA and a mean BCDVA equivalent to 20/20 vision, demonstrating [...]
Tenaya Therapeutics Presents Preclinical Data at MDA 2026 Highlighting TN-301’s Potential to Correct Skeletal and Cardiac Muscle Decline in Duchenne Muscular Dystrophy
09/03/2026
Tenaya’s Highly Selective HDAC6 Inhibitor TN-301 Outperformed Approved Pan-HDAC Inhibitor Givinostat in Improving Muscle Function and Correcting Drivers of DMD Cardiomyopathy New Data Confirm TN-301’s Differentiated [...]
Biodexa Announces Support for Life’s a Polyp Foundation First U.S. Patient Advocacy Group for FAP Patients
09/03/2026
March 9, 2026 Biodexa Announces Support for Life’s a Polyp Foundation First U.S. Patient Advocacy Group for FAP Patients Cardiff, UK – March 9, 2026 – Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage [...]
Nasus Pharma to Present Topline Analysis from NS002 Intranasal Epinephrine Powder Phase 2 Single and Repeat Dose Clinical Study
09/03/2026
TEL AVIV, March 09, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today [...]
BeautyHealth Expands Skin Health Ecosystem with Growing Adoption of SkinStylus Nano-Channeling, a Popular Pairing with Hydrafacial Treatments
09/03/2026
The Hydrafacial Treatment and SkinStylus Nano-Channeling Protocol Addresses Rising Consumer Demand for Combination Treatments That Can Improve Performance and Enhance Results LONG BEACH, Calif., March 09, 2026 (GLOBE [...]
SafeSpace Global Opens Nashville Office, Builds Operational Infrastructure to Support Revenue Growth
09/03/2026
Company Transitions from Remote Operations to Physical Facility; Plans Technology Demonstration Center, Expanded Workforce and Investor Events NASHVILLE, TN., March 09, 2026 (GLOBE NEWSWIRE) -- SafeSpace Global [...]
electroCore to Announce Fourth Quarter and Full Year Ended December 31, 2025, Financial Results on Thursday, March 19, 2026
09/03/2026
ROCKAWAY, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report financial results for the fourth [...]
Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting
09/03/2026
NEEDHAM, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies [...]
InspireMD to Announce Fourth Quarter and Full Year 2025 Financial Results
09/03/2026
MIAMI, March 09, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard ® Prime carotid stent system for the prevention of stroke, today announced that it will release its fourth quarter and [...]
Actuate Therapeutics Launches Strategic Research Initiative to Combine Elraglusib with RAS Inhibitors
09/03/2026
Inform future clinical development plans, further establishing elraglusib as a potential backbone therapy in difficult-to-treat cancers Mechanisms of action support enhanced activity of GSK-3 β plus RAS inhibition [...]
First-ever Dental Dedicated MRI Validated in Clinical Trial and Cleared by FDA for Advanced Soft-Tissue Diagnostics
09/03/2026
Dentsply Sirona and Siemens Healthineers are pleased to announce that the first-ever dental-dedicated MRI 1 (ddMRI) system – MAGNETOM Free.Max Dental Edition – has received FDA clearance in the United States. This [...]
Nasus Pharma to Present and Participate in the Upcoming Life Sciences Investor Forum
09/03/2026
TEL AVIV, March 09, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products to [...]

Pages